Flavonoids as DNA topoisomerase antagonists and poisons: Structure-activity relationships
AuthorConstantinou, Andreas I.
SourceJournal of natural products
Google Scholar check
MetadataShow full item record
Selected flavonoids were tested for their ability to inhibit the catalytic activity of DNA topoisomerase (topo) I and II. Myricetin, quercetin, fisetin, and morin were found to inhibit both enzymes, while phloretin, kaempferol, and 4',6,7-trihydroxyisoflavone inhibited topo II without inhibiting topo I. Flavonoids demonstrating potent topo I and II inhibition required hydroxyl group substitution at the C-3, C-7, C-3', and C-4' positions and also required a keto group at C-4. Additional B-ring hydroxylation enhanced flavonoid topo I inhibitory action. A C-2,C-3 double bond was also required, but when the A ring is opened, the requirement for the double bond was eliminated. Genistein has been previously reported to stabilize the covalent topo II-DNA cleavage complex and thus function as a topo II poison. All flavonoids were tested for their ability to stabilize the cleavage complex between topo I or topo II and DNA. None of the agents stabilized the topo I-DNA cleavage complex, but prunetin, quercetin, kaempferol, and apigenin stabilized the topo II DNA-complex. Competition experiments have shown that genistein-induced topo II-mediated DNA cleavage can be inhibited by myricetin, suggesting that both types of inhibitors (antagonists and poisons) interact with the same functional domain of their target enzyme. These results are of use for the selection of flavonoids that can inhibit specific topoisomerases at specific stages of the topoisomerization reaction. © 1995, American Chemical Society. All rights reserved.
Showing items related by title, author, creator and subject.
Cho, K. H.; Pezzuto, J. M.; Bolton, J. L.; Steele, V. E.; Kelloff, G. J.; Lee, S. K.; Constantinou, Andreas I. (2000)The present study was undertaken to determine if in vitro inhibition of one or both of the two most dominant mammalian DNA topoisomerases (topos) is common among chemopreventive agents. To determine if an agent was a topo ...
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: Pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials Fountzilas, George; Dafni, U.; Bobos, M.; Kotoula, V.; Batistatou, Anna; Xanthakis, I.; Papadimitriou, C.; Kostopoulos, I.; Koletsa, T.; Tsolaki, E.; Televantou, D.; Timotheadou, E.; Koutras, A. K.; Klouvas, G. D.; Samantas, E.; Pisanidis, N.; Karanikiotis, C.; Sfakianaki, I.; Pavlidis, Nicholas; Gogas, H.; Linardou, H.; Kalogeras, K. T.; Pectasides, Dimitrios; Dimopoulos, M. A. (2013)Background: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has ...
Commitment to erythroid differentiation in mouse erythroleukemia cells is controlled by alterations in topoisomerase IIα phosphorylation Constantinou, Andreas I.; Vaughan, A. T. M.; Yamasaki, H.; Kamath, N. (1996)To explore the program of cell differentiation in Friend murine erythroleukemia (MEL) cells, we used three clonal variants: phorbol 12- myristate 13-acetate (PMA)-hypersensitive TS-19-101, PMA-resistant TR19-9, and ...